BrYet US, Inc. (“BrYet”) — a biotechnology innovator focused on developing curative therapies for advanced cancers — ...

HOUSTON, TX / ACCESS Newswire / March 4, 2026 / BrYet US, Inc. ("BrYet") - a biotechnology innovator focused on ...

A new study by researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain ...

Gut microbiota may shape liver metastasis in small cell lung cancer and influence treatment response. Read more.

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

Real-world data show that Enhertu (fam-trastuzumab deruxtecan-nxki) was tolerated as well in the community setting, where patients had higher disease burden, as in the clinical trial setting, ...

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...

Scientists have developed an AI system that analyzes complex gene-expression signatures to estimate the likelihood that a tumor will spread.

A new study from researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain metastases, one of the most challenging and deadly complications of lung ...

Cancer spreads (metastasizes) when tumor cells shed from a primary solid tumor (for example, in the breast) and embed in ...

The research team developed a highly specialized type of immune cell, called a CAR macrophage, or CARMA, designed to find and attack tumor cells that spread to the brain. These engineered macrophages ...

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.